Robert Nelsen

Robert Nelsen

Net worth: 2 M $ as of 2026-05-30

62 year
Health Technology
Commercial Services
Finance

Profile

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners.
Some of his notable early-stage investments include Illumina (ILMN), Alnylam Pharmaceuticals (ALNY), June Therapeutics (JUNO – acquired by Celgene), Beam Therapeutics (BEAM), Karuna Therapeutics (KRTX), Altos Labs, EQRx (EQRX), National Resilience, Prime Medicine, Lyell Immunopharma (LYEL), Array BioPharma (ARRY – acquired by Pfizer), Hua Medicine (2552:HK), Vir Biotechnology (VIR), Insitro, Agios Pharmaceuticals (AGIO), Sage Therapeutics (SAGE), GRAIL (acquired by Illumina), Gossamer Bio (GOSS), Ikaria (acquired by Mallinckrodt), Kythera Biopharmaceuticals (KYTH – acquired by Allergan), Receptos (RCPT – acquired by Celgene), Aviron (AVIR – acquired by MedImmune), Denali Therapeutics (DNLI), Syros Pharmaceuticals (SYRS), Sana Biotechnology (SANA), Verve Therapeutics (VERV), Brii Biosciences (2137:HK), Bluebird Bio (BLUE), R2 Technology (acquired by Hologic), Caliper Life Sciences (CALP – acquired by PerkinElmer), Trubion Pharmaceuticals (TRBN – acquired by Emergent Biosolutions), Adolor (ADLR – acquired by Cubist Pharmaceuticals), deCODE Genetics (DCGN – acquired by Amgen), Editas (EDIT), 10x Genomics, Semma Therapeutics (acquired by Vertex Pharmaceuticals), Element, and IDUN Pharmaceuticals (acquired by Pfizer).
Mr. Nelsen is a director of VIR, SANA, LYEL, National Resilience, Insitro, Prime Medicine, Nutcracker Therapeutics, Neumora Therapeutics, Brii Biosciences, and serves as Chairman of Hua Medicine, among others.
He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute of Systems Biology, and was a director of the National Venture Capital association.
Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S.
from the University of Puget Sound with majors in Economics and Biology.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2025-03-30 60,615 ( 0.06% ) 2 M $ 2026-05-30
2026-06-04 100,142 ( 0.06% ) 355 504 $ 2026-05-30
2024-12-30 150,000 ( 0.01% ) 50 336 $ 2026-05-30
2026-06-03 13,853 ( 0.01% ) 45 715 $ 2026-05-30

Robert Nelsen active positions

CompaniesPositionStart
HUA MEDICINE (SHANGHAI) LTD. Chairman 2010-04-22
PRIME MEDICINE, INC. Director/Board Member 2020-08-31
SANA BIOTECHNOLOGY, INC. Founder 2018-07-12
Founder 2010-06-27
Director/Board Member 2021-12-31
Chairman -
Hua Medicine Technology (Hong Kong) Ltd.
Director/Board Member 2010-07-31
Director/Board Member -
Director/Board Member -
░░░░ ░░░░░░░ ░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░ ░░░░░ ░░░░░ ░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░ ░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░

Former positions of Robert Nelsen

CompaniesPositionEnd
░░░ ░░░░░░░░░░░░░░ ░░░░ ░░░░░░░ ░░░░░░░░░░
░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░░ ░░░░░ ░░░░░░░ ░░░░░░░░░░
See the detail of Robert Nelsen's experience

Training of Robert Nelsen

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

64

1st degree connections

80

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies80

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Finance

Finance

Process Industries

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Energy Minerals

Health Technology

Health Technology

Health Technology

Producer Manufacturing

Health Technology

Miscellaneous

Consumer Services

Technology Services

Consumer Services

Finance

Health Technology

Commercial Services

Health Technology

Commercial Services

Commercial Services

Commercial Services

Finance

Commercial Services

Health Technology

Finance

Commercial Services

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Technology Services

Health Technology

Hua Medicine Technology (Hong Kong) Ltd.

Health Technology

Health Technology

Health Technology

Commercial Services

Finance

Health Technology

Health Services

Health Technology

Health Technology

Finance

Commercial Services

Brii Biosciences (Beijing) Co. Ltd.

Brii Biosciences (Hong Kong) Co. Ltd.

Health Technology

Finance

Health Technology

Health Technology

Technology Services

Health Technology

Technology Services

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!